|15:00-15:05||Welcome and Introduction||Andreas Slama||TCAF|
|15:05-15:20||Introduction to GAiT and Promoting iPSC Therapies||Stephen Sullivan||Global Alliance for iPSC Therapies (GAiT)|
|15:20-15:35||Cellino: Making Patient-Derived iPSCs at Scale||Suvi Aivio||Cellino Biotech|
|15:35-15:50||StemSight: Treating Corneal Blindness with Stem Cells||Laura Koivusalo||StemSight|
|15:50-16:30||Panel Discussion||All speakers|
International Liaison Officer / Scientific Executive
Global Alliance for iPSC Therapies (GAiT)
Dr. Stephen Sullivan is GAiT’s International Liaison Officer. Previously he was Chief Scientific Officer at the Irish Stem Cell Foundation. He has held research positions at Harvard, Cambridge, Edinburgh, and UCSD researching therapeutic applications of human pluripotent stem cells. Additionally is a Fellow of the Royal Society of Medicine and has an MBA from Trinity College Dublin specialising in the economics of stem cell therapy development.
Suvi Aivio, PhD
Head of Biology at Cellino
Suvi Aivio is an expert in hiPSC reprogramming and differentiation. She started her career with stem cells in 2006 in Heli Skottman’s group at Regea (Tampere, Finland), and moved overseas to work with hematopoietic stem cells at UCLA in Hanna Mikkola’s group. After earning her PhD at the University of Pompeo Fabra in Barcelona, she returned to the US to do her postdoctoral studies at Harvard, focusing on differentiating iPSCs to skeletal muscle cells. Suvi joined Cellino in 2018. As Head of Biology, she leads the design and execution of iPSC-based experiments, ensures the successful transfer of manual biological processes to Cellino’s automated platform, and scouts new technologies to make the Cellino platform a world-leader in manufacturing patient-specific hiPSC-derived cell therapies.
Laura Koivusalo, DSc (Tech)
CEO and Founder of StemSight
In her doctoral thesis, Laura Koivusalo developed new biomaterials for delivering human stem cells to the surface of the eye. In September 2020, she graduated with distinction from Tampere University Eye Group. Together with three of her colleagues she founded the company StemSight in 2021, to take these stem cell-based therapies to patients suffering from untreatable blindness. StemSight’s goal is to manufacture off-the-shelf cell therapies for corneal blindness using human iPSCs. On the road to establish the company, Laura has won several pitching competitions in both Finland and abroad. She has also been awarded as the Young Outstanding Person of the Year in Medical Innovation in 2021 by JCI Finland.